China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. provided earnings guidance for the year ended 31 December 2022. For the year, the net profit attributable to the shareholders of CR Sanjiu for the year ended 31 December 2022 is estimated to range from approximately RMB2,365 million to RMB 2,570 million (as compared to the same period last year of net profit of approximately RMB2,055.6437 million), net profit attributable to the shareholders of CR Sanjiu excluding non-recurring gain or loss is estimated to range from approximately RMB 2,150 million to RMB 2,320 million (as compared to the same period last year of net profit of approximately RMB 1,852.9168 million), basic earnings per share is estimated to range from approximately RMB 2.4 per share to approximately RMB 2.61 per share (as compared to the same period last year of profit per share of approximately RMB 2.1 per share) (the "CR Sanjiu Results Estimate").